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hyper-high-density lipoprotein cholesterolemic
patients: a post hoc analysis of the MEGA study
Haruo Nakamura1*, Kyoichi Mizuno2 for the MEGA Study GroupAbstract
Background: The prognosis for hyper-high-density lipoprotein (HDL) cholesterolemic patients has not been fully
elucidated. We conducted a post hoc analysis of MEGA study data to investigate prospectively the incidence of
cardiovascular events and cancer in hyper-HDL cholesterolemic patients.
Methods: A total of 7832 patients with mild hypercholesterolemia were randomly allocated to either the National
Cholesterol Education Program step 1 diet alone (n = 3966) or the diet plus pravastatin (n = 3866) and followed for
5 years. The incidences of coronary heart disease (CHD), CHD plus cerebral infarction (CI), cardiovascular disease
(CVD), and cancer were calculated using the Cox proportional hazards model according to the level of HDL
cholesterol (HDL-C).
Results: CHD incidence was lower in patients with HDL-C >60–90 mg/dL (−52%, p = 0.0018) and HDL-C > 90 mg/dL
(−46%, p = 0.4007) than in patients with HDL-C ≤ 60 mg/dL. The incidences of CHD, CHD plus CI, and CVD were
significantly lower in patients with HDL-C >60–90 mg/dL than in those with HDL-C ≤ 60 mg/dL in both diet-alone and
diet-plus-pravastatin groups. Cancer incidence was not increased in patients with HDL-C >60–90 mg/dL.
Conclusion: Patients not receiving statin therapy should aim for a target HDL-C of between 60 and 90 mg/dL to
achieve a significant reduction in CHD without the occurrence of adverse events.
Trial registration: Clinical trials.gov NCT00211705.
Keywords: Randomized prospective study, Hyper-high-density lipoprotein cholesterolemia, Statin, Coronary heart
disease, CancerBackground
A low level of high-density lipoprotein cholesterol (HDL-
C) is one of the risk factors for cardiovascular disease
(CVD) [1]. A number of research programs are underway
with a view to increasing HDL-C and subsequently redu-
cing atherosclerotic clinical events. However, the extent to
which we should increase HDL-C and the prognosis for
patients with hyper-HDL cholesterolemia has not been
fully elucidated.
In Japan, 57% of individuals with HDL-C > 100 mg/dL
have mutations of the cholesterol ester transfer protein
(CETP) gene [2]. Furthermore, 37% of Japanese with* Correspondence: nakamura@mhwf.or.jp
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article, unless otherwise stated.HDL-C between 75 and 100 mg/dL have mutations of the
CETP gene [3].
Some genetic mechanisms that increase HDL-C do not
seem to lower the risk of myocardial infarction, for ex-
ample a single nucleotide polymorphism (SNP) in the
endothelial lipase gene [4]. In fact, lower plasma CETP ac-
tivity was not associated with a reduced incidence of CVD
in Framingham Heart Study participants [5]. Therefore it
remains unclear whether a lower incidence of atheroscler-
otic disease is associated with increasing the HDL-C level
or the genes that affect it.
In the primary prevention MEGA study [6] of the effects
of low-dose pravastatin in Japanese patients with mild-to-
moderate hypercholesterolemia and without CVD, total
cholesterol and low-density lipoprotein cholesterol (LDL-
C) were reduced by 12% and 18%, respectively. HDL-Cd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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disease (CHD) was significantly reduced by 33%.
The aim of the present study was to investigate pro-
spectively the incidence of cardiovascular events and
cancer in patients with hyper-HDL cholesterolemia in a
post hoc analysis of the MEGA study and the results are
reported in this article.
Results
Patient characteristics
The baseline characteristics of the patients according to
HDL-C level are shown in Table 1. Of the 7832 patients,
2936 (37.5%) had HDL-C > 60 mg/dL and 239 (3.1%) had
HDL > 90 mg/dL. The burden of atherosclerotic risk fac-
tors was less in patients with HDL-C > 60 mg/dL than in
those with HDL-C ≤ 60 mg/dL.
Table 2 shows the incidence of major CVD and death
in all patients according to HDL-C level.
The risk of CHD, CHD plus cerebral infarction (CI),
and all CVDs was significantly reduced in patients with
HDL-C between 60 and 90 mg/dL, adjusted for age, sex,
body mass index, hypertension, diabetes mellitus, LDL-C,
and smoking habit. In contrast, the risk of stroke or CI
was unchanged.
The incidence of cardiovascular events was also com-
pared in the diet-alone and diet-plus-pravastatin groups
separately (Figure 1). The hazard ratios for CHD, CHDTable 1 Baseline characteristics
HDL-C (mg/dL)
≤ 60 > 60 to ≤ 90 > 90
N 4896 2697 239
Age (years) 58.1 58.7 58.2
Male (%) 37.8 21.4a 19.7a
Body mass index (kg/m2) 24.4 23.0a 21.4a
Hypertension (%) 44.8 37.3a 33.5a
Diabetes mellitus (%) 23.2 17.0a 15.5a
Total cholesterol (mg/dL) 242.3 243.1 242.5
LDL-C (mg/dL) 161.3 150.9a 126.4a
HDL-C (mg/dL) 48.4 70.3a 97.0a
Triglycerides (mg/dL) 172.2 110.2a 80.5a
Non–HDL-C (mg/dL) 193.9 172.8a 143.5a
Lipoprotein(a) (mg/dL) 23.9 26.1a 25.7a
Blood pressure (mmHg)
Systolic 132.9 131.1a 130.0a
Diastolic 79.1 77.7a 77.8a
Fasting blood glucose (mg/dL) 110 105a 96a
Former or current smokers (%) 24.5 14.2a 13.4a
HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein
cholesterol.
aP < 0.01 versus ≤ 60 mg/dL group.plus CI, and CVD in the diet-alone and diet-plus-
pravastatin groups were significantly lower in patients
with HDL-C 60–90 mg/dL.
Conclusive evidence for a reduction in cardiovascular
risk was not obtained for patients with HDL-C > 90 mg/
dL. Two patients developed CHD during the follow-up
period. One of them was a 68-year-old woman with nor-
mal blood pressure (106/72 mmHg), normal LDL-C
(67.5 mg/dL) and triglycerides (81.7 mg/dL), no smoking
habit, and HDL-C of 142.8 mg/dL. She had angina with
coronary spasm, confirmed by coronary angiography.
The other was a 59-year-old woman with high blood
pressure (140–160/70–80 mmHg), normal LDL-C
(130.6 mg/dL), and no smoking habit. Her HDL-C was
97.5 mg/dL. She was admitted to hospital and treated
for angina confirmed by angiography.
Table 3 shows the incidence of cancer during the aver-
age 5.3-year follow-up period according to HDL-C level.
There were no significant differences in total incidence
of cancer or in incidence of cancer at any site according
to HDL-C level. Cancer incidence was further analyzed
in the diet-alone group and diet-plus-pravastatin group
separately. There were no significant differences in either
group according to HDL-C level (Figure 2).
Discussion
The results of this prospective study show that the inci-
dences of CHD, CHD plus CI, and CVD are reduced in
patients with HDL-C 60–90 mg/dL (i.e. mild hyper-HDL
cholesterolemia). This finding is consistent with the
results of a previous prospective study on Japanese-
American men in Hawaii [7] and an observational
prevalence study on the population of Western Japan
[8]. Elderly Japanese-American men in Hawaii with
heterozygous CETP deficiency and intermediate HDL-C
(41–60 mg/dL) have an increased prevalence of CHD [9].
However, the present study shows that patients with in-
creased HDL-C (>60 mg/dL) have a low risk of CHD re-
gardless of the presence of CETP abnormality.
The incidence of stroke and total death in this study
did not differ significantly between patients with HDL-
C ≤ 60 mg/dL and those with HDL-C > 60 mg/dL.
A recent study showed that some genetic mechanisms
that increase HDL-C do not seem uniformly to lower
the risk of myocardial infarction [4]. The authors tested
for an SNP in endothelial lipase. In most patients,
the presence of this SNP did not increase HDL-C
to > 60 mg/dL. Neither the mass nor activity of CETP
was available in this study. Plasma CETP activity was
measured in 1,978 participants of the Framingham Heart
Study, and lower CETP activity was found to be associ-
ated with greater risk of CVD [5]. However, there seems
to be no association between CETP activity and HDL-C
level, which remained to be at < 60 mg/dL.








95% CI p p for
trend
CHD ≤ 60 117/4896 (5.36) 1.0000 0.0066a 0.4007
> 60 to≤ 90 23/2697 (1.88) 0.4784 0.3011–0.7600 0.0018
> 90 2/239 (1.87) 0.5396 0.1280–2.2752 0.4007
Stroke ≤ 60 72/4896 (3.29) 1.0000 0.8803a 0.9729
> 60 to≤ 90 27/2697 (2.21) 0.8870 0.5565–1.4140 0.6144
> 90 0/239 (0.00) 0.0000 0.0000–0.0000 0.9729
Cerebral
infarction
≤ 60 53/4896 (2.41) 1.0000 0.6707a 0.9768
> 60 to≤ 90 17/2697 (1.39) 0.7696 0.4333–1.3670 0.3717
> 90 0/239 (0.00) 0.0000 0.0000–0.0000 0.9768
CHD plus cerebral
infarction
≤ 60 166/4896 (7.65) 1.0000 0.0048a 0.1425
> 60 to≤ 90 40/2697 (3.28) 0.5733 0.4002–0.8212 0.0024
> 90 2/239 (1.87) 0.3453 0.0834–1.4299 0.1425
Cardiovascular
disease
≤ 60 199/4896 (9.21) 1.0000 0.0099a 0.1043
> 60 to≤ 90 54/2697 (4.44) 0.6496 0.4746–0.8891 0.0071
> 90 2/239 (1.87) 0.3094 0.0751–1.2742 0.1043
Total deaths ≤ 60 82/4896 (3.66) 1.0000 0.0927a 0.2513
> 60 to≤ 90 26/2697 (2.09) 0.6335 0.4003–1.0023 0.0512
> 90 1/239 (0.91) 0.3091 0.0416–2.2980 0.2513
CHD coronary heart disease, CI confidence interval.
aP versus > 60 mg/dL group adjusted for age, sex, body mass index, hypertension, diabetes mellitus, low-density lipoprotein cholesterol, and smoking habit.
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CETP genotypes and the incidence of CHD have shown
higher HDL-C to have a weakly inverse association with
coronary risk [10]. Also, CETP-deficient families, includ-
ing heterozygous persons, have increased levels of HDL-C
(>60 mg/dL) and no evidence of premature atherosclerosis
[11].
A higher HDL-C level (>60 mg/dL) seems to be the
threshold for preventing CHD. However, two patients in
the diet-alone group developed CHD despite having
HDL-C > 90 mg/dL. One of these patients had hyperten-
sion and the other had HDL-C > 120 mg/dL, and both
developed spastic angina confirmed by coronary angiog-
raphy, which was relieved by the coadministration of ni-
trate and statin.
High-density lipoprotein plays several roles, including re-
verse cholesterol transport and endothelial, antioxidative,
and immunological functions. CETP inhibitors increase
HDL by promoting reverse cholesterol transport [12], with
small HDL remaining [13]. Therefore patients with spastic
angina may have had endothelial dysfunction. No cases of
angina were found in the diet-plus-pravastatin group in the
present analysis. Therefore the precise mechanism should
be clarified under further experimental conditions.
These findings suggest that the target threshold HDL-C
for patients not receiving statin therapy should be between60 and 90 mg/dL for them to achieve a significant reduc-
tion in CHD without the occurrence of adverse events.
Regarding the incidence of cancer, there were no sig-
nificant differences in the incidence of cancer at any site
according to HDL-C level. Cancer-related mortality was
reduced with statin use in previous studies [14,15].
To exclude selection bias, we separated the diet-alone
group from the diet-plus-pravastatin group. There were
no significant differences in the total incidence of cancer
or the incidence of cancer at different sites according to
HDL-C level.
The limitations of this study include the relatively short
follow-up period and the small number of participants.
However, the study included participants from all over
Japan (from Hokkaido in the north to Okinawa in the
south) approximately in proportion to the population in
different areas.
Three percent of patients with mild hypercholesterolemia
(total cholesterol ≥ 220 mg/dL) had hyper-HDL-C choles-
terolemia (HDL-C > 90 mg/dL) and 38% had mildly in-
creased HDL-C (>60 mg/dL). These figures are considered
to be representative for Japanese. Furthermore, figures for
the incidence of cardiovascular events and cancer were reli-
able because of the high follow-up rate (99.4%) [6].
Another limitation to this study is the lack of informa-
tion on the markers or mechanisms for the increase in











































































































Figure 1 Incidence of cardiovascular events according to high-density lipoprotein cholesterol level; in all patients (n = 7832), patients
in the diet-alone group (n = 3966), and patients in the diet-plus-pravastatin group (n = 3866) (5-year follow-up): (a) coronary heart
disease; (b) stroke; (c) cerebral infarction; (d), coronary heart disease plus cerebral infarction; (e) cardiovascular disease; and (f) total
deaths. *p < 0.05, **p < 0.01.
Nakamura and Mizuno Lipids in Health and Disease 2014, 13:133 Page 4 of 7
http://www.lipidworld.com/content/13/1/133HDL-C. However, this was not a purpose of the original
investigation. Also, a previous study has confirmed the
reduction in cardiovascular events in patients with high
HDL-C irrespective of the presence or absence of CETP
deficiency [8].
Conclusions
Patients with high HDL-C (>60 mg/dL) have a low inci-
dence of cardiovascular events, and the incidence of can-
cer was not increased at any site.
Methods
Patients
All 7832 MEGA study patients were included in this
post hoc analysis. The details of the MEGA study have
been reported [6]. Briefly, this prospective randomized,
open-label, blinded endpoint study was conducted inJapan between 1994 and 2004 in men and postmeno-
pausal women aged 40–70 years with a moderate level
of hypercholesterolemia (total cholesterol, 220–270 mg/
dL) and without a history of CHD or cerebrovascular
disease. A total of 3966 patients were randomly assigned
to the diet-alone group and 3866 patients to the diet-
plus-pravastatin group. Patients in both groups followed
the National Cholesterol Education Program step 1 diet.
Physicians and dieticians estimated that > 70% of pa-
tients adhered to the diet, with no significant differences
between the two groups. The dose of pravastatin was
10–20 mg/day, the approved dose range in Japan.
The primary endpoint was incidence of CHD defined
as a composite of fatal and non-fatal myocardial infarc-
tion, angina, cardiac sudden death, and revasculariza-
tion procedure. Secondary endpoints were stroke, CHD
plus CI, all cardiovascular events, and total mortality.
Table 3 Incidence of cancer according to high-density cholesterol level (during follow-up, all patients)
Cancer type High-density lipoprotein cholesterol (mg/dL) No. of patients (%) p
All ≤ 60 164/4896 (3.3) 0.5654
> 60 to≤ 90 77/2697 (2.9)
> 90 to≤ 120 6/225 (2.7)
> 120 0/14 (0.0)
Digestive organs ≤ 60 80/4896 (1.6) 0.6998
> 60 to≤ 90 38/2697 (1.4)
> 90 to≤ 120 5/225 (2.2)
> 120 0/14 (0.0)
Respiratory organs ≤ 60 13/4896 (0.3) 0.7093
> 60 to≤ 90 10/2697 (0.4)
> 90 to≤ 120 0/225 (0.0)
> 120 0/14 (0.0)
Breast ≤ 60 14/3045 (0.5) 0.7375
> 60 to≤ 90 12/2119 (0.6)
> 90 to≤ 120 0/185 (0.0)
> 120 0/7 (0.0)
Female reproductive organs ≤ 60 18/3045 (0.6) 0.3139
> 60 to≤ 90 6/2119 (0.3)
> 90 to≤ 120 0/185 (0.0)
> 120 0/7 (0.0)
Other ≤ 60 46/4896 (0.9) 0.2190
> 60 to≤ 90 14/2697 (0.5)
> 90 to≤ 120 1/225 (0.4)



















60 mg > 60 to 90 mg > 90 to 120 mg > 120 mg
Figure 2 Incidence of cancer according to high-density lipoprotein cholesterol level; in all patients (n = 7832), patients in the
diet-alone group (n = 3966), and patients in the diet-plus-pravastatin group (n = 3866) (during follow-up).
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start of follow-up, and every 6 months thereafter. All pa-
tients provided written informed consent. The trial was
conducted according to the ethical principles of the Dec-
laration of Helsinki and the Japanese Ministry of Health,
Labour and Welfare ordinance regarding post-marketing
surveillance. The MEGA study is registered at clinical
trials.gov as trial no. NCT00211705.Biochemical measurements
Blood samples were taken in the fasting state before
randomization and at the start of the study; 1, 3, and
6 months after the start of follow-up; and every
6 months thereafter. Total cholesterol and triglycerides
were measured by enzymatic methods. LDL-C was cal-
culated by using Friedewald’s formula [16]. All lipid
values were measured centrally in a blinded manner at
Special Reference Laboratory (SRL, Hachioji, Tokyo,
Japan), which is certified for major lipid measurement
by the Centers for Disease Control (Atlanta, GA, USA).
Biological markers related to the change in HDL-C were
not analyzed.
The subgroups of this study were classified as follows. In
the previous analysis, no significant differences were found
in the incidence of CHD between patients with HDL-C <
55 mg/dL and patients with HDL-C ≥ 55 mg/dL, using the
Cox proportional hazards model [6]. Therefore the cut-off
level for hyper-HDL cholesterolemia was increased to
60 mg/dL, with mild hyper-HDL cholesterolemia and
hyper-HDL cholesterolemia arbitrarily considered as HDL-
C > 60 and > 90 mg/dL, respectively.Statistical analyses
Baseline characteristics were compared across three
groups (patients with HDL-C ≤ 60 mg/dL, 60 < HDL-C ≤
90 mg/dL, and HDL-C > 90 mg/dL) using the chi-
squared test for categorical variables or the Wilcoxon
rank sum test for continuous variables. The incidence of
cardiovascular events and cancer was compared in all
patients, patients in the diet-alone group, and patients in
the diet-plus-pravastatin group. Hazard ratios and their
95% confidence intervals were calculated by using the
Cox proportional hazards model adjusted for baseline
risk factors, which were age, sex, body mass index,
hypertension, diabetes, LDL-C, and lipoprotein(a). All p
values were two-sided and a significance cut-off of 0.05
was used.Abbreviations
CETP: Cholesterol ester transfer protein; CHD: Coronary heart disease;
CI: Cerebral infarction; CVD: Cardiovascular disease; HDL-C: High-density
lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol;
SNP: Single nucleotide polymorphism.Competing interests
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